drugset / Trial / NCT02264028

Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL in 12 Healthy Male Volunteers

NCT02264028 ↗

Phase 1 Completed 12 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

* To investigate absorption, metabolism and excretion of \[14C\]-DK-AH 269 CL after oral and intravenous administration in healthy volunteers * To assess the safety and tolerability of DK-AH 269 CL after oral and intravenous administration to healthy volunteers

Timeline

Start
2004-03
Primary completion
2004-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Comparator [14C]-DK-AH 269 CL Unknown 5 mg Intravenous
Comparator [14C]-DK-AH 269 CL Unknown 10 mg Intravenous

Indications

No indication recorded.